USFDA warning letter hits Aurobindo Pharma's Telangana unit; stock falls 2%
Synopsis
The USFDA has escalated its regulatory action against Aurobindo Pharma's Telangana subsidiary Eugia Pharma Specialities, issuing a formal warning letter after an OAI classification — the agency's sharpest pre-import-alert signal. With Unit-I accounting for just 2% of group revenue and supplies to the US unaffected for now, the immediate financial hit is contained, but the compliance clock is ticking.
Key Takeaways
The USFDA issued a warning letter to Eugia Pharma Specialities Ltd (Aurobindo Pharma subsidiary) for its Unit-I facility in Telangana .
The facility was inspected between 16 February and 27 February ; the USFDA raised four observations and classified it under OAI status.
An earlier Form 483 issued in March had flagged nine observations .
Aurobindo Pharma says there is no impact on US market supplies and Unit-I contributes only ~2% of group revenue.
The stock fell more than 2% to an intraday low of ₹1,621.30 on the BSE on Friday.
In Q1 FY27 , Aurobindo Pharma posted a net profit of ₹1,032 crore on revenue of ₹9,150 crore .
Shares of Aurobindo Pharma dropped as much as 2 per cent on Friday, 14 August after the U.S. Food and Drug Administration (USFDA) issued a warning letter to a formulation manufacturing facility in Telangana operated by its subsidiary Eugia Pharma Specialities Ltd. The stock hit an intraday low of ₹1,621.30 on the BSE, according to the company's exchange filing.
What the Warning Letter Covers
The warning letter pertains to Unit-I, a formulation manufacturing facility of Eugia Pharma Specialities that the USFDA inspected between 16 February and 27 February this year. Following that inspection, the regulator issued four observations and classified the facility under 'Official Action Indicated' (OAI) status.
A warning letter from the USFDA signals that the agency has identified significant regulatory violations and is seeking corrective action from the manufacturer. The OAI classification indicates the regulator believes issues found during the inspection may warrant formal regulatory action.
Earlier Inspection History
Aurobindo Pharma had disclosed in March that the USFDA had, at the close of its inspection, issued a Form 483 carrying nine observations. The regulator subsequently determined the facility's classification as OAI before escalating to the current warning letter.
Company's Response and Supply Assurance
'There is no impact on the existing supplies to the U.S. markets,' Aurobindo Pharma said in its exchange filing. The company added that Unit-I contributes approximately 2 per cent to the group's overall revenue, limiting the immediate financial exposure from the development.
The drugmaker said it remains committed to working closely with the USFDA and is continuously strengthening its compliance systems.
Financial Context
In Q1 FY27, Aurobindo Pharma reported a net profit of ₹1,032 crore on revenue from operations of ₹9,150 crore. The pharma stock has a 52-week high of ₹1,682 and a 52-week low of ₹1,017, placing Friday's intraday low near the upper half of that range.
With the warning letter now in place, the company's next steps in resolving USFDA compliance observations at Unit-I will be closely watched by investors and regulators alike.
Point of View
The market reaction looks proportionate, but the deeper concern is reputational: repeated USFDA observations across different facilities raise questions about whether Aurobindo's compliance culture is keeping pace with its aggressive US market expansion.
NationPress
14 Aug 2026
Frequently Asked Questions
Why did the USFDA issue a warning letter to Aurobindo Pharma?
The USFDA issued a warning letter to Aurobindo Pharma's subsidiary Eugia Pharma Specialities after inspecting its Unit-I facility in Telangana between 16 February and 27 February. The inspection resulted in four observations and an 'Official Action Indicated' (OAI) classification, which the regulator escalated to a formal warning letter.
What is 'Official Action Indicated' (OAI) status?
OAI is a classification the USFDA assigns when it believes issues found during a facility inspection may require formal regulatory action. It is a serious designation that typically precedes a warning letter or, in more severe cases, an import alert.
Will the USFDA warning letter affect Aurobindo Pharma's US drug supplies?
Aurobindo Pharma has stated there is no impact on existing supplies to the US market. The company added that Unit-I contributes approximately 2% of group revenue, limiting the immediate financial effect of the regulatory action.
How did Aurobindo Pharma's stock react to the USFDA warning?
Shares of Aurobindo Pharma fell more than 2%, hitting an intraday low of ₹1,621.30 on the BSE on Friday, 14 August. The stock's 52-week range is ₹1,017 to ₹1,682.
What were Aurobindo Pharma's recent financial results?
In Q1 FY27, Aurobindo Pharma reported a net profit of ₹1,032 crore on revenue from operations of ₹9,150 crore, providing context for the limited revenue exposure from the affected Unit-I facility.
